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Identification of the PGRMC1 protein complex
as the putative sigma-2 receptor binding site
Jinbin Xu1, Chenbo Zeng1, Wenhua Chu1, Fenghui Pan1, Justin M. Rothfuss1, Fanjie Zhang1, Zhude Tu1,
Dong Zhou1, Dexing Zeng1, Suwanna Vangveravong1, Fabian Johnston2, Dirk Spitzer2, Katherine C. Chang3,
Richard S. Hotchkiss3, William G. Hawkins2, Kenneth T. Wheeler4 & Robert H. Mach1,5,6

The sigma-2 receptor, whose gene remains to be cloned, has been validated as a biomarker
for tumour cell proliferation. Here we report the use of a novel photoaffinity probe, WC-21,
to identify the sigma-2 receptor-binding site. WC-21, a sigma-2 ligand containing both a
photoactive azide moiety and a fluorescein isothiocyanate group, irreversibly labels sigma-2
receptors in rat liver; the membrane-bound protein was identified as PGRMC1 (progesterone
receptor membrane component 1). Immunocytochemistry reveals that both PGRMC1 and
SW120, a fluorescent sigma-2 receptor ligand, colocalize with molecular markers of the
endoplasmic reticulum and mitochondria in HeLa cells. Overexpression and knockdown of
the PGRMC1 protein results in an increase and a decrease in binding of a sigma-2 selective
radioligand, respectively. The identification of the putative sigma-2 receptor-binding site
as PGRMC1 should stimulate the development of unique imaging agents and cancer
therapeutics that target the sigma-2 receptor/PGRMC1 complex.
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S

igma-1 and sigma-2 receptors were initially characterized
in the mid-1970s using radioligand-binding studies1. Radio
labelled benzomorphans such as [3H]( + )-pentazocine bind
potently and selectively to sigma-1 versus sigma-2 receptors. Charac
terization of the sigma-2 receptor has relied on radioligand-binding studies using [3H]DTG (1,3 di-o-tolylguanidine) in the presence
of ( + )-pentazocine or dextrallorphan to block binding to sigma-1
receptors1. The sigma-1 receptor was purified, sequenced and cloned
from guinea pig brain in 1996, and shows no sequence homology
with any mammalian proteins cloned to date 2. Ligands binding to
the sigma-1 receptor modulate the release of neurotransmitters;
several of these compounds have shown promise as antipsychotics,
antidepressants and drugs blocking the effects of psychostimulants3,4.
Recent studies indicate that the sigma-1 receptor is expressed in postsynaptic sites, regulates ion channels, and may function as a protein
chaperone5–8. To date, the sigma-2 receptor has not been purified,
sequenced or cloned.
Although its structure is not known, the sigma-2 receptor has
been validated as a biomarker for tumour cell proliferation both
in vitro and in vivo, and as a target for chemotherapy. Several studies have shown that: the sigma-2 receptor density in proliferative
breast cancer cells is about tenfold higher than in quiescent breast
cancer cells9; sigma-2 receptor expression is upregulated during
the transition from quiescence to proliferation and downregulated
during the transition from proliferation to quiescence10; sigma-2
receptor density can be used to determine the proliferative status
of solid tumours11; sigma-2 receptor ligands can serve as chemotherapeutics for treating solid tumours12–14; and sigma-2 receptor

a

FITC

Azide

H
N

HO

H
N

O

S

b

Sigma-2 binding

N

OCH3

N3
O

25 kDa

OCH3

O
N
H

COOH

O

radioligands can be used to image tumours by positron emission
tomography or single-photon emission computed tomography15–19.
However, as the sigma-2 receptor gene has not been cloned, the
exact role this receptor has in tumour and normal cell proliferation
is currently unknown. Our group has developed sigma-2 selective
ligands, including [3H]RHM-1, [125I]RHM-4 and SW120 to directly
identify, locate and quantify this protein using a variety of receptorbinding and molecular imaging techniques13–15,18,20–22.
Progesterone receptor membrane component 1 (PGRMC1) is
overexpressed in a variety of tumours in comparison with the corresponding normal cells, and thus represents an important biomarker
for cancer progression and a potential target for anticancer drugs23–25.
PGRMC1, which exists in phosphorylated and dephosphorylated
states during cancer cell proliferation26, regulates cell growth and
proliferation through interactions between its Cytochrome b5-binding domain and other potential binding partners, which include
Insig-1, PAIR-BP1 and P450 proteins23,27–31. Recent studies suggest
that PGRMC1 is a biomarker of cell proliferation and an excellent
therapeutic target for inhibiting tumorigenesis24,32,33. Interestingly,
proteomic studies also showed that PGRMC1 is expressed in high
levels in the proliferative cells of human endometrium34.
The purpose of the current study was to identify the protein or
protein complex that contains the sigma-2 receptor ligand-binding
site as the first step in determining the role of this receptor in cell
proliferation, and defining a new target for the development of novel
tumour imaging agents and cancer therapeutics. Here we describe a
novel strategy developed for the identification of the sigma-2 receptor. The sigma-2 receptor photoaffinity probe, WC-21, an analogue
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Figure 1 | Identification of the putative sigma-2 receptor binding site as PGRMC1 using a novel photoaffinity probe. (a) WC-21 contains a FITC group
and a photoactive azide (N3) moiety, and displays high sigma-2 receptor affinity and selectivity; Ki = 8.7 ± 1 nM for sigma-2 receptor and Ki > 4,000 nM
for sigma-1 receptor. (b) Following ultraviolet crosslinking, ligand-labelled proteins were enriched and separated through SDS–polyacrylamide gel
electrophoresis; WC-21 crosslinked proteins can be visualized using an anti-FITC antibody; SS is silver staining and WB is western blot. (c) Proteomic
studies of the FITC-positive band identified two proteins, which shared the same genetic name: progesterone receptor membrane component 1 (PGRMC1).
The protein structure shows the peptides (bold) detected by mass spectrometry as well as the Cytochrome b5 domain (underlined).
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The pharmacological profile of [125I]RHM-4 in HeLa cells.
[125I]RHM-4 (Fig. 2a) is a useful radioligand for measuring sigma-2
receptor density in tumours and normal tissues19. AG-205, a reported
PGRMC1 ligand33,37, and the known sigma-2 receptor ligands, DTG,
siramesine, SV119 and WC-26, readily displaced [125I]RHM-4 binding in HeLa cell membrane homogenates (Fig. 2a). Similar results
were also observed in mouse mammary 66 tumour cell membrane
homogenates (Supplementary Fig. S5).
Binding activity in PGRMC1 siRNA and cDNA-treated HeLa
cells. Because PGRMC1 is a known protein, a number of molecular biology tools are available to study the relationship between
the expression of this protein and the binding of sigma-2 selective ligands in cancer cells. Knockdown studies using a PGRMC1specific short interfering (siRNA; Fig. 2b) reduced the binding of
[125I]RHM-4 to HeLa cells (Fig. 2c), indicating that the PGRMC1
complex has binding properties similar to the sigma-2 receptor.
Similar results were observed in human embryonic kidney 293T
cells using the PGRMC1-specific siRNA and the sigma-2 selective
fluorescent probe, SW120 (Supplementary Fig. S6). Cells treated
with non-targeting siRNA were used as controls. Overexpression
studies were also conducted in HeLa cells using a cDNA for
PGRMC1. HeLa cells transfected with the PGRMC1 cDNA displayed an increase in protein levels (Fig. 2d) and a 60% increase
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Results
Photoaffinity labelling and protein identification. The synthesis of
sigma-2 receptor photoaffinity probe WC-21 is described in detail
in the supporting online material (Supplementary Figs S1–S3). WC21 has high binding affinity for sigma-2 receptors (Ki = 8.7 nM) and
relatively low binding affinity for sigma-1 receptors (Ki > 4,000 nM;
Fig. 1a). WC-21 was incubated with rat liver membrane homogenates,
and the WC-21–protein complex photo-crosslinked. The protein
supernatant was enriched and separated by gel electrophoresis
(Fig. 1b). Western blot analysis revealed a dominant protein band
at ~24 kDa that was labelled by FITC-conjugated probe WC-21
(Fig. 1b). Labelling of this protein band with WC-21 could be blocked
by well-characterized sigma-2 receptor ligands (Supplementary
Fig. S4). Proteomic studies of the protein in the ~24 kDa band
identified two proteins, the 22 kDa putative progesterone-binding
protein and the 25 kDa 25-Dx protein, that share the same genetic
name, PGRMC1. Figure 1c shows the protein sequence of the two
peptides, gdqpgasgdndddeppplpr and dftpaelr, detected
by mass spectrometry and the Cytochrome b5 domain (underlined)
of PGRMC1. The gene for PGRMC1 is located on q22–q24 of the X
chromosome23.
Three other proteins, glutathione-S-transferase alpha type 2,
glutathione S-transferase mu 1 (with two matched peptides), and
NADH dehydrogenase (ubiquinone) flavoprotein 2 (with one
matched peptide), were identified from the proteomics study. Based
on the localization of sigma-2 receptors within the plasma membrane9,35,36, endoplasmic reticulum and mitochondria21,22, these proteins were excluded as potential candidates, as they are all intracellular
enzymes, which happen to overlap the PGRMC1 protein band.

F

Specific binding (% control)

of RHM-1, contains an azide moiety for the photoaffinity tagging of
the sigma-2 receptor, and a fluorescein isothiocyanate group (FITC)
for protein visualization. WC-21 was utilized to directly label the
sigma-2 receptor-binding site in rat hepatic membrane homogenates. Proteomic studies and consequent studies were carried out
to determine the molecular identity of the sigma-2 receptor binding site and if it corresponded to any previously identified proteins.
PGRMC1 was identified as the putative sigma-2 receptor binding
site. The results of our studies provide strong experimental evidence
supporting the localization of the putative sigma-2 receptor binding
site within the PGRMC1 protein complex.

150
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Vector control

PGRMC1 cDNA

Figure 2 | The pharmacological profile of [125I]RHM-4 and sigma-2
receptor-binding activity in PGRMC1 siRNA- and cDNA-treated HeLa
cells. (a) Competitive binding studies of [125I]RHM-4 were carried out
with the PGRMC1 ligand AG-205, sigma-2 receptor ligands DTG, WC-26,
SV119 and siramesine or with the sigma-1 receptor ligand ( + )-pentazocine.
[125I]RHM-4 binding was blocked by AG-205 and the sigma-2 ligands but
not by ( + )-pentazocine. N = 2, sample in triplicate. (b) Typical western
blot confirming PGRMC1 protein expression knockdown in PGRMC1specific siRNA-treated HeLa cells relative to non-targeting siRNA-treated
controls compared with actin (loading control). (c) The bar graph shows
reduced sigma-2 receptor-binding activity in the PGRMC1 knockdown
cells; *P < 0.01, Student’s t-test, n = 3. (d) Typical western blot confirming
increased PGRMC1 protein expression in PGRMC1-transfected HeLa cells
relative to vector-transfected controls. (e) Bar graph showing increased
sigma-2 receptor-binding activity in PGRMC1-transfected cells; *P < 0.01,
Student’s t-test, n = 3. Error bars in a, c, e represent s.e.m.

in binding of [125I]RHM-4 (Fig. 2e) over cells transfected with
vector alone. Sigma-1 receptor-binding activities, determined
using [3H]( + )-pentazocine, were found to be not changed in the
non-targeting siRNA and PGRMC1 siRNA-treated cells, or in
cells transfected with vector and PGRMC1 cDNA (Supplementary Fig. S7).
Sigma-2 receptor and PGRMC1 in mammary 66 and 67 cells.
A good correlation between sigma-2 receptor binding of [125I]
RHM-4 and the PGRMC1/actin ratio was observed in mouse
mammary adenocarcinoma cells lines 66 and 67 after 6 (proliferative cells), 12 (early quiescent phase) and 18 (late quiescent phase)
days in culture (Supplementary Fig. S8). These data are consistent
with the expression of sigma-2 receptors in 66 and 67 cells9.
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Figure 3 | Caspase-3 activation and PGRMC1 upregulation induced by
the sigma-2 receptor ligand, WC-26. (a) Chemical structure of WC-26, a
selective sigma-2 receptor ligand. (b) Knockdown of PGRMC1 in HeLa cells
resulted in decreased caspase-3 activation induced by WC-26. (c) WC-26
stimulated PGRMC1 expression in the same manner as AG-205 (ref. 34),
a PGRMC1 ligand; *P < 0.01, Student’s t-test, n = 3. Error bars in b represent
s.e.m.

Caspase-3 activation and PGRMC1 upregulation by WC-26.
Studies have shown that sigma-2 receptor ligands can induce caspase-3-dependent cell death14,38. In the current study, functional
assays were conducted to examine the ability of the PGRMC1 to
regulate caspase-3 activation by the sigma-2 receptor ligand, WC26 (Fig. 3a). In HeLa cells, knocking down the PGRMC1 resulted
in a blunting of the effect of WC-26 to induce caspase-3 activation
relative to HeLa cells treated with the non-targeting siRNA (Fig. 3b).
Also, previous studies have shown that AG-205, a PGRMC1 ligand,
induced an upregulation of PGRMC1 in A549 lung cancer cells33,37.
The sigma-2 receptor ligand WC-26 induced an upregulation of
PGRMC1 protein in a dose-dependent manner in non-targeting
siRNA-treated cells (Fig. 3c). Only a minimal increase in PGRMC1
expression was observed in the PGRMC1 knockdown cells.
Intracellular localization of PGRMC1 and sigma-2 receptors.
The intracellular localization of PGRMC1 and sigma-2 receptors
was compared using confocal microscopy. PGRMC1 proteins were
visualized with an anti-PGRMC1 antibody, whereas sigma-2 receptors were visualized using the fluorescent probe, SW120 (ref. 21;


Figure 4 | Intracellular co-localization of PGRMC1 and sigma-2 receptors
in HeLa cells using confocal microscopy. (a) Sigma-2 receptors labelled
with SW120 and PGRMC1 partially colocalized with mitochondria markers
(b, c) and endoplasmic reticulum markers (d, e) in HeLa cells. For imaging
sigma-2 receptors, live cells were incubated with SW120 and either
MitoTracker or ER-Tracker and then imaged by confocal microscopy. For
imaging PRGMC1, cells were fixed and incubated with goat anti-PGRMC1
antibody followed by a FITC-conjugated secondary antibody. Antibody
stained HeLa cells were then coverslipped and imaged by confocal
microscopy. Scale bar represents 20 µm.

Fig. 4a). Both the sigma-2 receptor probe (Fig. 4b,d) and antiPGRMC1 antibody (Fig. 4c,e) colocalized with markers of the
mitochondria (Fig. 4b,c) and the endoplasmic reticulum (Fig. 4d,e).
An additional set of high-magnification images are shown in
Supplementary Figure S9.

Discussion
In recent years, considerable effort has been focused on the identification of cancer biomarkers, which could be used in early detection, patient prognosis and prediction of response to different
types of chemo- and radiotherapy. In many regards, the sigma-2
receptor possesses a unique ability to serve as both a diagnostic and
therapeutic biomarker of solid tumours. The tenfold higher density
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of sigma-2 receptors in proliferating breast cancer cells versus quiescent breast cells in vitro and in vivo9,11 suggests that measuring
the sigma-2 receptor status of solid tumours should provide an
assessment of the proliferating/quiescent cell ratio in solid tumours,
which could be used by an oncologist to select between certain types
of chemotherapy (for example, cell cycle specific versus cell cycle
nonspecific) and radiation therapy (hyperfractionated versus conventional radiation therapy). Furthermore, preclinical studies of
sigma-2 receptor agonists have shown promise as chemotherapeutic agents, as they are capable of killing tumour cells via a variety of
mechanisms including caspase- and non-caspase-mediated apoptosis. However, the widespread acceptance of the sigma-2 receptor as a
cancer biomarker has been hampered by the fact that the molecular
identity of this protein was not known.
The goal of the current study was to complete a series of
steps aimed at determining the molecular identity of the sigma-2
receptor. The first step involved the development of a sigma-2 selective photoaffinity probe, which could irreversibly tag sigma-2 receptors in rat liver membrane homogenates, the tissue source used in
sigma-2 receptor-binding assays. The photoaffinity labelling and
mass spectrometry sequence analysis indicated that a strong candidate protein for the sigma-2 receptor was PGRMC1. A review of the
literature revealed a number of similarities between the expression
of PGRMC1 in cancer cells and normal tissues, and the density of
sigma-2 receptors in the same cancer cells and tissues. The availability of siRNA, cDNA and monoclonal antibodies for PGRMC1
provided the tools needed to study the relationship between the
expression of this protein and the binding of sigma-2 selective
ligands in cancer cells. The intracellular localization of PGRMC1
and sigma-2 receptors in mitochondria and endoplasmic reticulum,
reduction in sigma-2 receptor-binding and caspase-3-mediated cell
deaths in PGRMC1 siRNA-treated HeLa cells, and the increase in
sigma-2 receptor binding upon overexpressing the PGRMC1 clearly
demonstrate that sigma-2 receptor ligands bind to the PGRMC1
protein complex. Therefore, this study is the first to report that the
putative sigma-2 receptor ligand-binding site is located within the
PGRMC1 protein complex. In addition, the observations that AG205, a reported PGRMC1 ligand, displaces [125I]RHM-4 from HeLa
cell membrane homogenates, and that both AG-205 and the sigma2 receptor ligand WC-26 induce an upregulation of the PGRMC1
protein in lung cancer cells33,37 and HeLa cells further support our
conclusions.
The identification that the putative sigma-2 receptor binding
site resides within the PGRMC1 protein complex is significant
for many reasons. First, it provides a link between receptor-binding studies using sigma-2 radioligands and a known protein, the
PGRMC1, which has been validated as a biomarker of cancer and
cell proliferation. Second, it provides a gene whose expression can
be examined across a wide panel of tumour cells. The genetic mutations and single-nucleotide polymorphism of PGRMC1 can also
be readily examined in assessing the possible roles of this gene
in normal cell function and in malignant transformation. Finally,
the results reported here provide an important scientific bridge
between the sigma-2 receptor and the PGRMC1, and make available a variety of radioligands, fluorescent probes and potential small
molecule ligands to study the sigma-2 receptor/PGRMC1 complex
in solid tumours and cancer cells using a variety of experimental
techniques.

Methods

Chemical synthesis of the compounds and radiotracers. The tritiated compound, [3H]RHM-1, was made by American Radiolabelled Chemicals, Inc. via
O-alkylation of the corresponding phenol precursor17,20; the specific activity of the
radioligand was 80 Ci mmol − 1. [3H]( + )-Pentazocine was purchased from
Perkin-Elmer. [125I]RHM-4 was prepared by an iododestannylation reaction of
the corresponding tributyltin precursor13,19. SV119, SW120 and WC-26, and
siramesine were synthesized by our group according to published methods12,21,39,40.

The synthesis of the novel FITC-conjugated probe, WC-21 (Supplementary
Figs S1–S3), is described in the Supplementary Methods. AG-205 was purchased
from TimTec. DTG and ( + )-pentazocine were purchased from Sigma Aldrich.
Haloperidol was purchased from Tocris Bioscience. PGRMC1 recombinant protein
was purchased from Assay Designs, Inc.
Cell membrane and hepatic membrane homogenates. Human HeLa and human
embryonic kidney 293T cells were grown in minimum essential media (MEM)
containing 10% fetal bovine serum, 2 mM l-glutamine, 1% nonessential amino
acids and 1× penicillin/streptomycin at 37 °C in a humidified 5% CO2/95% air
atmosphere. The mouse mammary tumour 66 cells were grown as previously
described9. The cells were harvested from T75 flasks after 6, 12 or 18 days in
culture. For binding assays, cells were mechanically scraped, rinsed with ice-cold
phosphate-buffered saline (PBS), transferred to a 15 ml conical centrifuge tube
and centrifuged for 10 min at 200g. The cell pellet from each T75 flask was
resuspended in 1 ml of 50 mM Tris-HCl at pH 8.0, and homogenized using an
Ultra-Turrax T8 polython homogenizer (IKA Works, Inc.) at speed 3 for 20 s.
Hepatic cell membrane homogenates were prepared from the liver of male
Sprague–Dawley rats, as previously described20.
Photoaffinity labelling and protein identification. For photoaffinity labelling, 100 nM of WC-21 was incubated in a 96-well plate with rat liver membrane
homogenates (~300 µg of protein in a volume of 150 µl) for 1 h, then the reactions
were stopped and filtered into 96-well filter plate after being washed three times.
The washed filters were irradiated with 254-nm ultraviolet light for 2 min at a
distance of 1 cm; the protein-loaded filters were then punched out, pooled and
crushed by homogenization in 2% SDS solution in a 15-ml centrifuge tube,
following a centrifugation of 10 min at speed of 800 g, the supernatant was mixed
with protein gel sample buffer and boiled for 2 min.
For western blot analysis of the WC-21-labelled protein band, lysates
containing 35 µg of protein were run on a 12% acrylamide gel and transferred to
a polyvinylidene fluoride membrane (Bio-Rad Laboratories). The position of the
predominant band of the ligand-labelled protein in the gel was determined
using a horseradish peroxidase-conjugated goat anti-FITC antibody (Biodesign
International Inc.) at a 1:1,000 dilution (Supplementary Fig. S3).
Western blot analysis with a horseradish peroxidase (HRP)-conjugated antiFITC antibody revealed the predominant protein band at ~24 kDa was labelled by
WC-21 (Fig. 1b). This protein band labelling could be blocked by sigma-2 receptor
ligands, such as DTG, haloperidol and RHM-1 (Supplementary Fig. 3). The 24 kDa
band on the silver stained gel was excised and trypsinized; the trypsinized protein
solution was further confirmed as tagged with WC-21 an antibody specific for
FITC. Proteomic study of the protein solution identified two proteins, the 22-kDa
putative progesterone-binding protein and the 25-kDa 25-Dx protein, which share
the same genetic name, PGRMC1.
For sequencing studies, proteins were enriched by SDS–polyacrylamide gel
electrophoresis on 4–15% gradient gels using ~100 µg of protein per loading well.
Ten gel pieces containing proteins ranging from 20–26 kDa molecular weight
were excised and subjected to electro-elution with Midi GeBAflex-tube (Gerard
Biotech). The eluted protein samples were dialyzed with 7,000 MWCO SnakeSkin
pleated dialysis tubing (Pierce Biotechnology, Inc.) and lyophilized; the enriched
protein sample was further separated with two 12% gels. One gel was silver stained
for protein band visualization using a Mass spectrometry compatible kit from
Bio-Rad Laboratories and the other gel was transferred to a polyvinylidene fluoride
membrane for western blot analysis with a HRP-conjugated anti-FITC antibody
(Fig. 1b). The FITC-positive protein band was found at molecular weight of 24 kDa,
which was determined using the protein standards. The 24 kDa band was excised
and trypsinized. Matrix-assisted laser desorption/ionization–mass spectrometry
analysis of the trypsinized proteins was performed by the Proteomics and Mass
Spectrometry facility of the Donald Danforth Plant Science Center to identify
the proteins.
PGRMC1 siRNA treatment. HeLa cells were plated on 6-well plates at a cell
density of 1.5×105 cells per well. At 24 h after plating, the cells were treated with
either non-targeting siRNA (catalogue number D-001210-02-20, Thermo Scientific
Dharmacon, Inc.) or human PGRMC1 siRNAs (catalogue number L-010642-000020, Thermo Scientific Dharmacon, Inc.) mixed with DharmaFECT 2 Transfection Reagent (Thermo Scientific Dharmacon, Inc.) to yield a final concentration
of 50 nM. siRNA transfection was performed according the siRNA transfection
protocol outlined by Dharmacon. At 48 h after siRNA treatment, cells were
collected for the sigma-2 receptor-binding assay. The silencing of PGRMC1 was
confirmed by western blot analysis.
Overexpression of PGRMC1. HeLa cells were plated in 100-mm dishes at 1.5×106
per dish. At 24 h after plating, the cells were transfected with the pCMV6-XL4
vector only or human PGRMC1 cDNA (OriGene Technologies, Inc.) using a
Fugene 6 transfection reagent (Roche Applied Science). Transfection was carried
out according to the guidelines of the manufacturer. For transfection of HeLa cells,
18 µl of Fugene 6 and 10 µg human PGRMC1 cDNA were used. After 24 h, the
cells were collected for the sigma-2 receptor-binding assays. The overexpression of
PGRMC1 was confirmed by western blot analysis.
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Caspase-3 activation assay. WC-26-induced caspase-3 activation in PGRMC1
siRNA-treated HeLa cells was quantified by flow cytometry using a FACScan (BD
Biosciences) equipped with an air-cooled argon laser. HeLa cells were fixed in 70%
ethanol, washed twice with PBS, and incubated with rabbit anti-cleaved-caspase-3
antibody (Cell Signaling Technology) at a 1:50 dilution in BD Perm/Wash buffer
(BD Biosciences) for 2 h at 37 °C. The cells were washed three times with PBS,
and then incubated with phycoerythrin-conjugated donkey anti-rabbit IgG
(BD Biosciences Pharmingen; 1:300 dilution) for 1 h at room temperature. After
washing with PBS, 5 µl of 7-amino-actinomycin D (7-AAD, BD Biosciences) was
added at a concentration of 0.25 µg of 7-AAD per 1×106 cells. The phycoerythrinconjugated antibody was excited at 488 nm, and the emission collected using
a 570 nm filter. The 7-AAD was excited at 488 nm, and the emission collected using
a 650-nm long-pass filter.
Immunocytochemistry of sigma-2 receptors and PGRMC1. MitoTracker Red
CMXRos and ER-Tracker Red dye were purchased from Invitrogen Corporation.
HeLa cells were plated in 35-mm diameter glass-bottom dishes at 2×105 cells per
dish for 24 h. The live cells were incubated with 30 nM SW120 and either the
mitochondria tracker, MitoTracker Red CMXRos (20 nM), or the endoplasmic
reticulum tracker, ER-Tracker Red (500 nM), for 2 h at 37 °C. The labelled cells were
then coverslipped and imaged by confocal microscopy, as previously described21,22.
The images were acquired using a confocal laser scanning microscope (LSM5
Pascal, Carl Zeiss). SW120 was excited using the 488 nm line from an argon laser,
and the emission collected through a 505–530 nm band-pass filter. MitoTracker
and ER-Tracker were excited using the 543 nm line from a helium–neon laser, and
the emission collected through a 560-nm long-pass filter.
For imaging PRGMC1, fixed HeLa cells were incubated with goat antiPGRMC1 antibody at a 1:100 dilutions in the blocking serum overnight at 4 °C.
After washing, the cells were incubated with FITC-conjugated donkey anti-goat
IgG secondary antibody for 1 h. Rabbit anti-COX IV antibody (Cell signaling) and
rabbit anti-GRP78 BiP antibody (Abcam) were used for imaging Mito-marker and
ER-marker, respectively. The secondary antibody used for imaging Mito-marker
and ER-marker is TRITC-conjugated donkey anti-rabbit IgG. The FITC and
TRITC antibody-labelled cells were then coverslipped and imaged by confocal
microscopy.
Methods for receptor-binding assay, western blot analysis of PGRMC1,
real-time PCR for PGRMC1 mRNA expression and synthesis of the novel
photoaffinity probe WC-21 and the 1H nuclear magnetic resonance and 13C
nuclear magnetic resonance spectra for compounds 2, 3, 4, 5 and WC-21
(Supplementary Figs S10–S19) are detailed in the Supplementary
Information.
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